China NMPA grants first-in-world approval for novel biopharmaceutical therapy

China's National Medical Products Administration has approved a novel, globally trialled medicine ahead of the US, Japan, and EU regulators. This marks a strategic shift in China's pharmaceutical sector, signaling an intent to accelerate domestic innovation and compete directly with established global markets in drug development.